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ABSTRACT
A rapid method combining gyrA PCR–restriction
fragment length polymorphism analysis, parC
PCR and adonitol fermentation was developed
to identify Klebsiella pneumoniae phylogenetic
groups KpI, KpII and KpIII. Analysis of 420
clinical isolates from 26 hospitals showed that the
three groups were widespread geographically.
KpI comprised 80.3% of 305 isolates from blood
and 82.2–97.2% of isolates from other clinical
sources. KpIII was never found among isolates
from urinary tract infections. KpI isolates from
blood were generally less susceptible than KpIII
isolates to the ten antimicrobial agents tested,
with KpII being intermediate. The frequencies of
ceftazidime resistance were 21.6% and 8.6% in
KpI and KpIII isolates, respectively (p 0.01).
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and soft tissue infections [1,2]. Klebsiella pneumo-
niae is responsible for 75–80% of Klebsiella infec-
tions, with antimicrobial resistance, particularly
that associated with extended-spectrum b-lacta-
mases, posing an increasingly serious problem
[3–6]. Based on nucleotide variation of the gyrA
and parC genes, clinical isolates of K. pneumoniae
fall into three phylogenetic groups named KpI,
KpII and KpIII [7], with the newly described
species Klebsiella variicola [8] appearing to corres-
pond to KpIII [8] (S. Brisse, unpublished results).
The present study aimed to develop a rapid
method for the identification of these phylogenet-
ic groups, to determine their relative prevalence
in nosocomial infections, and to compare their
levels of antimicrobial susceptibility.
In total, 420 clinical isolates (including 120
isolates investigated previously [7]) and eight
reference strains were studied. The 420 clinical
isolates were collected from 23 hospitals located
in 13 European countries and three hospitals in
South Africa [4,9], and were derived from blood
(n = 305), nosocomial respiratory tract infections
(n = 56), urinary tract infections (UTIs; n = 35),
and wound infections (n = 24). Only one isolate ⁄
patient was included.
In-silico restriction analysis of a 441-bp PCR
fragment of the gyrA gene (gyrA PCR–restriction
fragment length polymorphism (PCR-RFLP)) [7]
revealed that use of TaqI and HaeIII separately
would distinguish between KpI (profiles TaqI-B,
HaeIII-C), KpII (TaqI-E, HaeIII-C or HaeIII-D) and
KpIII (TaqI-B and HaeIII-B). PCR-RFLP patterns
were obtained by digestion of the amplified PCR
fragment [7] and electrophoresis on a NuSieve
GTG agarose 3% w ⁄v gel. Identification of Kle-
bsiella spp. remains difficult [10], and profile
HaeIII-B was also obtained for all control strains
of Klebsiella oxytoca (n = 29), Klebsiella planticola
(n = 15) and Klebsiella terrigena (n = 5) tested.
However, enzyme HincII did not cut the gyrA
PCR products from K. planticola and K. terrigena,
whereas it generated profile HincII-B (298 bp and
143 bp) for all K. pneumoniae isolates and profile C
(196 bp, 168 bp and 77 bp) for all isolates of
K. oxytoca.
Use of the above technique confirmed that all
420 clinical isolates were K. pneumoniae. TaqI and
HaeIII restriction profiles were as expected for
isolates for which the gyrA gene had been
sequenced previously [7] (Fig. 1). In total, 345
(82.1%) clinical isolates were identified as KpI, 29
(6.9%) as KpII and 46 (11%) as KpIII. The gyrA
and parC genes of a further 60 randomly selected
clinical isolates (45 KpI, eight KpII and seven
KpIII) were sequenced, and gyrA PCR-RFLP
group identification was confirmed in all cases.
The property of adonitol fermentation was
shown previously to be distributed unequally
among the phylogenetic groups [7]. In the present
study, 336 (97.4%) of 345 KpI isolates were
adonitol-positive, with the nine adonitol-negative
isolates confirmed as KpI by parC sequencing. For
KpII, 19 (65.5%) of 29 isolates were adonitol-
positive, whereas only two (4.3%) of 46 KpIII
isolates were positive, with these two isolates
confirmed as KpIII by parC sequencing.
In order to confirm group identification, a KpII-
specific PCR assay targeting the parC gene was
tested on 220 of the 420 isolates identified previ-
ously by gyrA PCR-RFLP. Primers parC2-
1 (GGCGCAACCCTTCTCCTAT) and parC2-3
(GAGCAGGATGTTTGGCAGG) were designed
to match KpII sequences, but to have mismatches
compared to KpI and KpIII sequences [7]. The
positions of the primers did not include sites
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Fig. 1. Examples of restriction profiles obtained after
cutting the 441-bp gyrA PCR product with enzymes TaqI
and HaeIII. The profile codes are indicated by a letter above
each lane. M: molecular size marker (300-bp, 200-bp and
100-bp fragments). Profile TaqI-B consists of the expected
197-bp, 142-bp, 93-bp and 9-bp fragments, and profile TaqI-
E of the expected 197-bp, 151-bp and 93-bp fragments.
Profile HaeIII-B consists of the expected 175-bp, 174-bp and
92-bp fragments, profile HaeIII-C of the expected 175-bp,
129-bp, 92-bp and 45-bp fragments, and profile D (not
shown) of the expected 267-bp, 129-bp and 45-bp frag-
ments.
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involved in quinolone resistance. PCR amplifica-
tion with a 50C annealing temperature yielded
the expected 232-bp product with none of 146 KpI
and 45 KpIII isolates tested, whereas 28 of 29 KpII
isolates were positive. The discrepant KpII isolate
was confirmed to be KpII by parC sequencing.
Thus, the KpII-specific parC PCR showed excel-
lent specificity (100%) and sensitivity (97%) for
detection of KpII strains.
Overall, the results indicated that gyrA PCR-
RFLP assigns isolates reliably to one of the three
K. pneumoniae groups. Although less informative
than gene sequencing, gyrA PCR-RFLP provides
information faster and at a lower cost than gyrA
sequencing, but identification should ideally be
confirmed with independent markers. KpI was
found in all 26 hospitals, KpII in 16 hospitals, and
KpIII in 17 hospitals. KpI was the most common
group in clinical specimens from most hospitals
(80.3–83.3% from blood, respiratory tract infec-
tions and wounds, and 97.2% from UTIs); KpIII
was never found in UTIs.
The MICs of ten antimicrobial agents were
determined for the 420 clinical isolates by
National Committee for Clinical Laboratory
Standards broth microdilution methods [11].
Resistance rates in UTI, blood and respiratory
tract infection isolates, respectively, were 42%,
22% and 14% for ceftazidime, 61%, 44% and
28% for piperacillin, 42%, 24% and 14% for
co-trimoxazole, 21%, 13% and 19% for gentami-
cin, and 9%, 4% and 6% for ciprofloxacin. Similar
trends were observed for most other antimicrobial
agents. Table 1 compares the results for blood
isolates of the three K. pneumoniae groups. For
most agents, the level of resistance was highest in
KpI, intermediate in KpII, and lowest in KpIII.
The difference between KpI and KpIII resistance
levels was statistically significant (p £ 0.01) for
ceftazidime (indicating extended-spectrum b-lac-
tamase production) and piperacillin. Piperacillin
resistance levels were statistically different
between KpII and KpIII (p 0.0005). Resistance
to ampicillin was significantly different between
KpI and KpII (p 0.001) and between KpI and
KpIII (p < 0.0001), mostly because of KpII and
KpIII isolates with intermediate resistance (MIC
16 mg ⁄L). The differences for ampicillin and
piperacillin resistance remained statistically sig-
nificant even if only the 216 KpI, 21 KpII and 32
KpIII ceftazidime-susceptible blood isolates
(MIC £ 16 mg ⁄L) were considered. For many
antimicrobial agents, the resistance rate in KpI
isolates was two- or three-fold higher than that
in KpIII isolates. Resistance levels are higher in
K. pneumoniae than in K. oxytoca isolates [4], but
resistance rates in KpIII isolates appear similar
or lower to those observed in K. oxytoca. Resist-
ance was not clustered in particular hospitals, so
the differences in antimicrobial susceptibility
among K. pneumoniae groups cannot be attrib-
uted to over-representation of a few resistant
strains following clonal spread. The higher pre-
valence of KpI isolates could be a consequence of
higher resistance rates, since resistance is a
critical parameter for the transmission of this
mainly nosocomial and opportunistic pathogen
[12,13].
In summary, reliable identification of the three
K. pneumoniae phylogenetic groups can be
obtained by combining gyrA PCR-RFLP, parC
PCR and adonitol fermentation. For isolates with
discrepant results, parC gene sequencing can be
used for confirmation. The different distribution
and frequencies of antimicrobial resistance
observed in this study suggest distinctive patho-
genic and epidemiological characteristics among
the three groups, which may be relevant for the
control of K. pneumoniae infections.
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Table 1. Proportions of susceptible, intermediate and
resistant blood isolates of the three K. pneumoniae phylo-
genetic groups
Susceptible (%) Intermediate (%) Resistant (%)
KpI KpII KpIII KpI KpII KpIII KpI KpII KpIII
Ampicillin 0 4 0 1.2 4.0 22.8 98.8 92.0 87.2
Piperacillin 35.5 28.0 80.0 21.6 36.0 8.6 42.9 36.0 11.4
Piperacillin–
tazobactam
80.4 88.0 94.3 4.1 0 0 15.5 12.0 5.7
Ceftazidime 88.4 84.0 91.4 0 0 0 21.6 16.0 8.6
Ceftriaxone 88.0 84.0 91.4 5.3 0 0 16.7 16.0 8.6
Imipenem 100 100 100 0 0 0 0 0 0
Gentamicin 82.6 93.6 94.3 2.8 3.2 0 14.6 3.2 5.7
Amikacin 93.1 93.6 94.3 6.9 3.2 5.7 0 3.2 0
Trimethoprim–
sulphamethoxazole
77.2 92.0 88.6 – – 22.8 8.0 11.4
Ciprofloxacin 92.6 88.0 97.1 3.7 0 0 3.7 12.0 2.9
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ABSTRACT
Matrix proteins of viruses within the order
Mononegavirales have similar functions and play
important roles in virus assembly. Protein
sequence alignment, phylogenetic tree derivation,
hydropathy profiles and secondary structure pre-
diction were performed on selected matrix pro-
tein sequences, using human respiratory syncytial
virus matrix protein as the reference. No general
conservation of primary, secondary or tertiary
structure was found, except for a broad similarity
in the hydropathy pattern correlating with the
fact that all the proteins studied are membrane-
associated. Interestingly, the matrix proteins of
Ebola virus and human respiratory syncytial
virus shared secondary structure homology.
Keywords Ebola virus, matrix protein, Mononegavi-
rales, respiratory syncytial virus, RNA viruses
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Matrix proteins of negative-sense single-strand
RNA viruses play an important role in virus
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